The deal includes an upfront payment, which Foster City-based Gilead (NASDAQ: GILD) did not disclose, and additional development, regulatory and commercial milestone payments.
Wednesday, October 5, 2011
Gilead strikes licensing deal with Boehringer Ingelheim on new HIV drug
The deal includes an upfront payment, which Foster City-based Gilead (NASDAQ: GILD) did not disclose, and additional development, regulatory and commercial milestone payments.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment